These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37091809)

  • 21. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 22. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
    Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
    Front Genet; 2022; 13():1068462. PubMed ID: 36712872
    [No Abstract]   [Full Text] [Related]  

  • 23. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
    Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
    Front Immunol; 2022; 13():994828. PubMed ID: 36405728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-Cancer Analysis of the Oncogenic and Immunological Role of
    Ding J; Meng Y; Han Z; Luo X; Guo X; Li Y; Liu S; Zhuang K
    Front Oncol; 2022; 12():811567. PubMed ID: 35651805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of
    Wei C; Zhao Y; Ji T; Sun Y; Cai X; Peng X
    Front Oncol; 2022; 12():865409. PubMed ID: 35480115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. lncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer.
    Xue C; Yi C; Lin H; Zhao J; Yuan J; Chen Y; Chen H; Lin L; Zhao Y
    Dis Markers; 2022; 2022():4317480. PubMed ID: 35432631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer.
    Zhao YY; Xiang QM; Chen JL; Zhang L; Zheng WL; Ke D; Shi RS; Yang KW
    Front Oncol; 2022; 12():990247. PubMed ID: 36338724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Pan-Cancer Analysis Confirmed That ATG5 Promoted the Maintenance of Tumor Metabolism and the Occurrence of Tumor Immune Escape.
    Xu C; Zang Y; Zhao Y; Cui W; Zhang H; Zhu Y; Xu M
    Front Oncol; 2021; 11():652211. PubMed ID: 33842365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the roles and driving forces of CCT3 in human tumors.
    Ma J; Song P; Liu X; Ma C; Zheng M; Ren X; Wang R; Liu W; Lu Z; Li J
    Front Pharmacol; 2022; 13():1005855. PubMed ID: 36313331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer.
    Liu S; Wang Z; Hu L; Ye C; Zhang X; Zhu Z; Li J; Shen Q
    Transl Oncol; 2024 Jul; 45():101982. PubMed ID: 38718436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of immune infiltration-related LncRNA FAM83C-AS1 for predicting prognosis and immunotherapy response in colon cancer.
    Li G; Feng H; Chen Q; Xue C; Li M; Liu X; Ma S
    Transpl Immunol; 2021 Dec; 69():101481. PubMed ID: 34624486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer.
    Chen C; Shang A; Gao Y; Huang J; Liu G; Cho WC; Li D
    Front Mol Biosci; 2022; 9():968458. PubMed ID: 36203873
    [No Abstract]   [Full Text] [Related]  

  • 34. GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers.
    Jin D; Yuan L; Li F; Wang S; Mao Y
    BMC Med Genomics; 2022 Apr; 15(1):75. PubMed ID: 35365175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer.
    Lu Y; Wang W; Liu Z; Ma J; Zhou X; Fu W
    Mol Med; 2021 Aug; 27(1):83. PubMed ID: 34344319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the oncogenic roles of LINC00857 in pan-cancer.
    Ren X; Liu J; Wang R; Liu X; Ma X; Lu Z; Hu Z; Zheng M; Ma J; Li J
    Front Pharmacol; 2022; 13():996686. PubMed ID: 36160408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.
    Qiu J; Wu X; Luo Y; Yao Y; Zhang X; Pan B; Wang X; Tang N
    Gene; 2023 Mar; 856():147132. PubMed ID: 36566982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
    Guo X; Zhou L; Wu Y; Li J
    Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of PLOD2.
    Xu Q; Kong N; Zhao Y; Wu Q; Wang X; Xun X; Gao P
    Front Genet; 2022; 13():864655. PubMed ID: 35586565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.